B+
Bull case
25%
Probability
Target price
$150.00
+100.0% vs current
Since IPO, investors praise TAM and product fit but remain cautious on near-term margins and lock-up selling [#PR-2024-12-11], [#SEC-424B4]. Analysts see upside if ARR monetization accelerates; short interest and Form 4s indicate caution.
No evidence quality warning is currently attached to this memo.
Quarterly results could move consensus growth and margin outlook; sources: company IR and 10-Q/10-K [#10Qp1], [#PR-2024-12-11].
Insider selling after lock-up expirations could pressure the stock; monitor Form 4 activity [#SEC-424B4].
Upsell within the contractor base could drive durable ARR expansion and margin improvement [#10Kp3], [#PR-2024-12-11].
No formal recommendation provided.